371 related articles for article (PubMed ID: 25349154)
1. TGIF1 is a negative regulator of MLL-rearranged acute myeloid leukemia.
Willer A; Jakobsen JS; Ohlsson E; Rapin N; Waage J; Billing M; Bullinger L; Karlsson S; Porse BT
Leukemia; 2015 May; 29(5):1018-31. PubMed ID: 25349154
[TBL] [Abstract][Full Text] [Related]
2. PBX3 and MEIS1 Cooperate in Hematopoietic Cells to Drive Acute Myeloid Leukemias Characterized by a Core Transcriptome of the MLL-Rearranged Disease.
Li Z; Chen P; Su R; Hu C; Li Y; Elkahloun AG; Zuo Z; Gurbuxani S; Arnovitz S; Weng H; Wang Y; Li S; Huang H; Neilly MB; Wang GG; Jiang X; Liu PP; Jin J; Chen J
Cancer Res; 2016 Feb; 76(3):619-29. PubMed ID: 26747896
[TBL] [Abstract][Full Text] [Related]
3. Initiation of MLL-rearranged AML is dependent on C/EBPα.
Ohlsson E; Hasemann MS; Willer A; Lauridsen FK; Rapin N; Jendholm J; Porse BT
J Exp Med; 2014 Jan; 211(1):5-13. PubMed ID: 24367003
[TBL] [Abstract][Full Text] [Related]
4. Linkage of the potent leukemogenic activity of Meis1 to cell-cycle entry and transcriptional regulation of cyclin D3.
Argiropoulos B; Yung E; Xiang P; Lo CY; Kuchenbauer F; Palmqvist L; Reindl C; Heuser M; Sekulovic S; Rosten P; Muranyi A; Goh SL; Featherstone M; Humphries RK
Blood; 2010 May; 115(20):4071-82. PubMed ID: 20237320
[TBL] [Abstract][Full Text] [Related]
5. MiR-495 is a tumor-suppressor microRNA down-regulated in MLL-rearranged leukemia.
Jiang X; Huang H; Li Z; He C; Li Y; Chen P; Gurbuxani S; Arnovitz S; Hong GM; Price C; Ren H; Kunjamma RB; Neilly MB; Salat J; Wunderlich M; Slany RK; Zhang Y; Larson RA; Le Beau MM; Mulloy JC; Rowley JD; Chen J
Proc Natl Acad Sci U S A; 2012 Nov; 109(47):19397-402. PubMed ID: 23132946
[TBL] [Abstract][Full Text] [Related]
6. Meis1 is an essential and rate-limiting regulator of MLL leukemia stem cell potential.
Wong P; Iwasaki M; Somervaille TC; So CW; Cleary ML
Genes Dev; 2007 Nov; 21(21):2762-74. PubMed ID: 17942707
[TBL] [Abstract][Full Text] [Related]
7. Identification of MLL-fusion/MYC⊣miR-26⊣TET1 signaling circuit in MLL-rearranged leukemia.
Huang H; Jiang X; Wang J; Li Y; Song CX; Chen P; Li S; Gurbuxani S; Arnovitz S; Wang Y; Weng H; Neilly MB; He C; Li Z; Chen J
Cancer Lett; 2016 Mar; 372(2):157-65. PubMed ID: 26791235
[TBL] [Abstract][Full Text] [Related]
8. TET1 plays an essential oncogenic role in MLL-rearranged leukemia.
Huang H; Jiang X; Li Z; Li Y; Song CX; He C; Sun M; Chen P; Gurbuxani S; Wang J; Hong GM; Elkahloun AG; Arnovitz S; Wang J; Szulwach K; Lin L; Street C; Wunderlich M; Dawlaty M; Neilly MB; Jaenisch R; Yang FC; Mulloy JC; Jin P; Liu PP; Rowley JD; Xu M; He C; Chen J
Proc Natl Acad Sci U S A; 2013 Jul; 110(29):11994-9. PubMed ID: 23818607
[TBL] [Abstract][Full Text] [Related]
9. ZNF521 sustains the differentiation block in MLL-rearranged acute myeloid leukemia.
Germano G; Morello G; Aveic S; Pinazza M; Minuzzo S; Frasson C; Persano L; Bonvini P; Viola G; Bresolin S; Tregnago C; Paganin M; Pigazzi M; Indraccolo S; Basso G
Oncotarget; 2017 Apr; 8(16):26129-26141. PubMed ID: 28412727
[TBL] [Abstract][Full Text] [Related]
10. PBX3 is essential for leukemia stem cell maintenance in MLL-rearranged leukemia.
Guo H; Chu Y; Wang L; Chen X; Chen Y; Cheng H; Zhang L; Zhou Y; Yang FC; Cheng T; Xu M; Zhang X; Zhou J; Yuan W
Int J Cancer; 2017 Jul; 141(2):324-335. PubMed ID: 28411381
[TBL] [Abstract][Full Text] [Related]
11. Expression of HOX genes, HOX cofactors, and MLL in phenotypically and functionally defined subpopulations of leukemic and normal human hematopoietic cells.
Kawagoe H; Humphries RK; Blair A; Sutherland HJ; Hogge DE
Leukemia; 1999 May; 13(5):687-98. PubMed ID: 10374871
[TBL] [Abstract][Full Text] [Related]
12. EVI1 is critical for the pathogenesis of a subset of MLL-AF9-rearranged AMLs.
Bindels EM; Havermans M; Lugthart S; Erpelinck C; Wocjtowicz E; Krivtsov AV; Rombouts E; Armstrong SA; Taskesen E; Haanstra JR; Beverloo HB; Döhner H; Hudson WA; Kersey JH; Delwel R; Kumar AR
Blood; 2012 Jun; 119(24):5838-49. PubMed ID: 22553314
[TBL] [Abstract][Full Text] [Related]
13. Pediatric acute myeloid leukemia with NPM1 mutations is characterized by a gene expression profile with dysregulated HOX gene expression distinct from MLL-rearranged leukemias.
Mullighan CG; Kennedy A; Zhou X; Radtke I; Phillips LA; Shurtleff SA; Downing JR
Leukemia; 2007 Sep; 21(9):2000-9. PubMed ID: 17597811
[TBL] [Abstract][Full Text] [Related]
14. A role for MEIS1 in MLL-fusion gene leukemia.
Kumar AR; Li Q; Hudson WA; Chen W; Sam T; Yao Q; Lund EA; Wu B; Kowal BJ; Kersey JH
Blood; 2009 Feb; 113(8):1756-8. PubMed ID: 19109563
[TBL] [Abstract][Full Text] [Related]
15. The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia.
Baker A; Gregory GP; Verbrugge I; Kats L; Hilton JJ; Vidacs E; Lee EM; Lock RB; Zuber J; Shortt J; Johnstone RW
Cancer Res; 2016 Mar; 76(5):1158-69. PubMed ID: 26627013
[TBL] [Abstract][Full Text] [Related]
16. HOXA9 is required for survival in human MLL-rearranged acute leukemias.
Faber J; Krivtsov AV; Stubbs MC; Wright R; Davis TN; van den Heuvel-Eibrink M; Zwaan CM; Kung AL; Armstrong SA
Blood; 2009 Mar; 113(11):2375-85. PubMed ID: 19056693
[TBL] [Abstract][Full Text] [Related]
17. DOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated leukemogenesis.
Nguyen AT; Taranova O; He J; Zhang Y
Blood; 2011 Jun; 117(25):6912-22. PubMed ID: 21521783
[TBL] [Abstract][Full Text] [Related]
18. miR-196b directly targets both HOXA9/MEIS1 oncogenes and FAS tumour suppressor in MLL-rearranged leukaemia.
Li Z; Huang H; Chen P; He M; Li Y; Arnovitz S; Jiang X; He C; Hyjek E; Zhang J; Zhang Z; Elkahloun A; Cao D; Shen C; Wunderlich M; Wang Y; Neilly MB; Jin J; Wei M; Lu J; Valk PJM; Delwel R; Lowenberg B; Le Beau MM; Vardiman J; Mulloy JC; Zeleznik-Le NJ; Liu PP; Zhang J; Chen J
Nat Commun; 2012 Feb; 3():688. PubMed ID: 22353710
[TBL] [Abstract][Full Text] [Related]
19. A novel small molecule that kills a subset of MLL-rearranged leukemia cells by inducing mitochondrial dysfunction.
Somers K; Wen VW; Middlemiss SMC; Osborne B; Forgham H; Jung M; Karsa M; Clifton M; Bongers A; Gao J; Mayoh C; Raoufi-Rad N; Kusnadi EP; Hannan KM; Scott DA; Kwek A; Liu B; Flemming C; Chudakova DA; Pandher R; Failes TW; Lim J; Angeli A; Osterman AL; Imamura T; Kees UR; Supuran CT; Pearson RB; Hannan RD; Davis TP; McCarroll J; Kavallaris M; Turner N; Gudkov AV; Haber M; Norris MD; Henderson MJ
Oncogene; 2019 May; 38(20):3824-3842. PubMed ID: 30670779
[TBL] [Abstract][Full Text] [Related]
20. The PAF complex regulation of Prmt5 facilitates the progression and maintenance of MLL fusion leukemia.
Serio J; Ropa J; Chen W; Mysliwski M; Saha N; Chen L; Wang J; Miao H; Cierpicki T; Grembecka J; Muntean AG
Oncogene; 2018 Jan; 37(4):450-460. PubMed ID: 28945229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
